A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan
To verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer.

* Primary Endpoint: Relapse-free survival (RFS)
* Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate, safety profile
Resected Pancreatic Cancer|Pancreatic Cancer|Adjuvant Chemotherapy
DRUG: S-1
Relapse-free survival (RFS), The time from registration to the time of initial detection of relapse or death from any causewhichever came first, assessed up to 2 years, 2 years
2-year survival rate, The number of patient who occur relapse or death from any cause, whichever comes first before end of 2 years, 2 years|2-year relapse-free survival (RFS) rate, the percentage of people in a study who are alive 2 years after their diagnosis or the start of treatment, 2 years|safety profile, The incidence and percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v5.0 grade, 2 years
To verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer.

* Primary Endpoint: Relapse-free survival (RFS)
* Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate, safety profile